DS-5565
PreclinicalSmall molecule
Daiichi SankyoDS-5565 is one of 11 small molecule programs targeting Neuralgia. It is currently in Preclinical.
1
Indications
10
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
10 competitors in Neuralgia
#DrugCompanyPhaseTrials
1Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cymbalta
Jazz PharmaceuticalsApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Marcaine
IInnocoll
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Fycompa
CCatalyst Biosciences
Approved
TRD205
BBeijing Tide Pharmaceutical Co., Ltd
Phase 2
Journavx
Vertex PharmaceuticalsPreclinical
Cymbalta
Jazz PharmaceuticalsPreclinical
DS-5565
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fibromyalgia4 trials
Peripheral Neuropathy2 trials
Chronic Kidney Disease1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DS-5565. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company